Adverse events66

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

41 to 60 of 66

Type	Event	Organ system	Group	Affected	At risk
other	Dermatitis	Skin and subcutaneous tissue disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
other	Dermatitis	Skin and subcutaneous tissue disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	2	34
other	Hypertension	Vascular disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
other	Hypertension	Vascular disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	2	34
serious	Iron deficiency anaemia	Blood and lymphatic system disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
serious	Iron deficiency anaemia	Blood and lymphatic system disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	1	34
serious	Adrenal insufficiency	Endocrine disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
serious	Adrenal insufficiency	Endocrine disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	1	34
serious	Colitis ulcerative	Gastrointestinal disorders	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	2	57
serious	Colitis ulcerative	Gastrointestinal disorders	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	2	34
serious	COVID-19 pneumonia	Infections and infestations	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
serious	COVID-19 pneumonia	Infections and infestations	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	1	34
serious	Gastroenteritis	Infections and infestations	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
serious	Gastroenteritis	Infections and infestations	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	1	34
serious	Staphylococcal bacteraemia	Infections and infestations	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
serious	Staphylococcal bacteraemia	Infections and infestations	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	1	34
serious	Upper respiratory tract infection	Infections and infestations	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
serious	Upper respiratory tract infection	Infections and infestations	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	1	34
serious	Colon cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks	0	57
serious	Colon cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks	1	34

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous page Next page

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03648541/events?page=3

API reference For AI assistants